Travel industry calls on White House to end Covid-19 testing requirement for travelers from overseas

Travel industry calls on White House to end Covid-19 testing requirement for travelers from overseas


A man checks in at a Covid-19 testing site in the international arrivals area of Los Angeles International Airport in Los Angeles, California on December 22, 2021.

Frederic J. Brown | AFP | Getty Images

Travel and hospitality CEOs are stepping up pressure on the Biden administration to scrap a requirement that anyone flying into the U.S. present a a negative Covid-19 test before departure, saying the rule is discouraging visitors and hurting the country’s tourism industry.

The push comes after the United Kingdom, Italy, Greece and others have lifted similar requirements as pandemic restrictions ease around the world.

In the U.S., health officials still require travelers flying into the country to provide proof of a negative Covid-19 test, regardless of their vaccination status or citizenship. People can also present proof that they recovered from Covid. Other countries including South Korea and Japan also require travelers to present a negative Covid test.

“Requiring pre-departure testing creates uncertainty for travelers, one more hurdle that may lead them to choose a destination with less friction,” Marriott CEO Tony Capuano said in a statement to CNBC. “The U.S. will miss out if we don’t eliminate those unnecessary barriers.”

Nearly 40 U.S. mayors including from San Francisco and Miami also sent a letter this week to Dr. Ashish Jha, the White House Covid-19 coordinator, urging him to lift the requirement. The letter said American cities are still struggling to regain international visitors.

Travel industry executives also met with Jha last week, but say they didn’t get a timeline for when the requirement might end.

“They are unable to cite when predeparture testing will be lifted,” Tori Barnes, president of the U.S. Travel Association, told CNBC after the meeting.

The White House did not respond to a request for comment.

“Predeparture testing is holding international travelers back from bookings a trip to the U.S.,” said Jon Bortz, CEO of Pebblebrook Hotel Trust, which owns 54 hotels around the country.

Glenn Fogel, CEO of the world’s largest online travel operator, Booking Holdings, said the test requirement is pushing people to visit other countries. In other cases, he noted people just find ways around the requirement.

“We also see instances of people simply avoiding the restriction by flying into Canada or Mexico and driving across the board,” Fogel said in a statement.

In a note to investors Wednesday, Morgan Stanley analyst Jamie Rollo wrote that the testing requirement is becoming especially concerning for cruise travelers, who worry about being stuck on a ship testing positive.

Keith Barr, CEO of InterContinental Hotels Group, expressed frustration with the country’s testing requirement on CNBC’s “Closing Bell” Tuesday.

“It’s out of step with the rest of the world,” he said.



Source

2026 is the year of obesity pills. Here’s how they could reshape the GLP-1 market
Health

2026 is the year of obesity pills. Here’s how they could reshape the GLP-1 market

The booming GLP-1 space was built on weekly injections. In 2026, new obesity pills will push the market into its next chapter. Patients are already getting their hands on the first GLP-1 pill for obesity from Danish drugmaker Novo Nordisk — a once-daily drug that shares the same brand name as its popular injection Wegovy. […]

Read More
Healthy Returns: What to expect from pharma at the JPM conference
Health

Healthy Returns: What to expect from pharma at the JPM conference

Heidi Overton, Novo Nordisk CEO Maziar Mike Doustdar, Eli Lilly CEO David A. Ricks, and U.S. Secretary of Commerce Howard Lutnick listen while U.S. President Donald Trump announces a deal with Eli Lilly and Novo Nordisk on to reduce the prices of GLP-1 weight‑loss drugs during an event in the Oval Office at the White […]

Read More
A little-known biotech stock has become a prime takeover target after surging nearly 1,700% last year
Health

A little-known biotech stock has become a prime takeover target after surging nearly 1,700% last year

Europe’s best-performing blue-chip stock in 2025 is widely expected to be bought by a larger peer, in a deal analysts say could be worth as much as $23 billion. Abivax, the French clinical-stage biotech company developing a treatment for ulcerative colitis and Crohn’s disease, saw shares rocket 1,681% last year, far outpacing the Stoxx 600 […]

Read More